Idys LLIF 3DTi

K202032 · Clariance, Sas · OVD · Apr 1, 2021 · Orthopedic

Device Facts

Record IDK202032
Device NameIdys LLIF 3DTi
ApplicantClariance, Sas
Product CodeOVD · Orthopedic
Decision DateApr 1, 2021
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3080
Device ClassClass 2
AttributesTherapeutic

Intended Use

The Idys® LLIF 3DTi system is intended for use in patients with degenerative disc disease (DDD) at one (1) or two (2) contiguous level(s) of the lumbosacral spine (L2-S1). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. These DDD patients may also have up to Grade I Spondylolisthesis or retrolisthesis at the involved level(s). These patients should be skeletally mature and have had at least six (6) months of non-operative treatment. The Idys® LLIF 3DTi system is intended to be used with bone graft and/or allogeneic bone graft composed of cancellous and/or corticocancellous bone and with cleared supplemental fixation in addition to the integrated plate and screws.

Device Story

Lumbar intervertebral body fusion system; used for spinal stabilization in DDD patients. Device consists of titanium alloy cage with porous lattice structure; features integrated plate and screws. Implanted via lateral surgical approach; restores intervertebral height and lordosis. Cage contains slots for bone graft to promote fusion. Porous surface provides grip to vertebral endplates to resist expulsion. Used by surgeons in clinical/OR settings. Benefits patient by providing structural support and scaffold for bone fusion, reducing back pain.

Clinical Evidence

Bench testing only. No clinical data. Mechanical testing included static/dynamic axial compression, static/dynamic compression shear, expulsion testing, static torsion, and particle characterization per ASTM F2077 and F2267. Biocompatibility confirmed per ISO 10993-5 and -11. Sterilization validated per ISO 11737 and ISO 11137.

Technological Characteristics

Medical grade Titanium alloy (ASTM F136, ASTM F3001). Additive manufacturing process creates porous lattice structure. System includes cage, integrated plate, and two bone screws. Dimensions vary by footprint, height, and lordotic angle. Standalone implant; requires supplemental fixation. Sterilized via validated methods.

Indications for Use

Indicated for skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels of the lumbosacral spine (L2-S1), including those with up to Grade I Spondylolisthesis or retrolisthesis, who have failed at least six months of non-operative treatment.

Regulatory Classification

Identification

An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.

Special Controls

*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters 'FDA' in a blue square, followed by the words 'U.S. FOOD & DRUG ADMINISTRATION' in blue text. April 1, 2021 CLARIANCE, SAS % Janice M. Hogan Partner Hogan Lovells US LLP 1735 Market Street, 23rd Floor Philadelphia, Pennsylvania 19103 Re: K202032 Trade/Device Name: Idys® LLIF 3DTi Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral Body Fusion Device Regulatory Class: Class II Product Code: OVD Dated: March 9, 2021 Received: March 9, 2021 Dear Ms. Hogan: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {1}------------------------------------------------ Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely. Brent L. Showalter, Ph.D. Assistant Director DHT6B: Division of Spinal Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ 510(k) Number (if known) K202032 Device Name ldys® LLIF 3DTi #### Indications for Use The Idys® LLF 3DTi system is intended for use in patients with degenerative disc disease (DDD) at one (1) or two (2) contiguous level(s) of the lumbosacral spine (L2-S1). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. These DDD patients may also have up to Grade I Spondylolisthesis or retrolisthesis at the involved level(s). These patients should be skeletally mature and have had at least six (6) months of nonoperative treatment. The Idys® LLF 3DTi system is intended to be used with bone graft composed of cancellous and/or corticocancellous bone and with cleared supplemental fixation to the integrated plate and screws. Type of Use (Select one or both, as applicable) 区 Prescription Use (Part 21 CFR 801 Subpart D) _ Over-The-Counter Use (21 CFR 801 Subpart C) ## CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. ### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ ### K202032 ## 510(k) SUMMARY # CLARIANCE's Idys® LLIF 3DTi # Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared ### CLARIANCE 18 rue Robespierre F-62217 Beaurains, France Phone: +33 (0)3 21 16 12 15 Facsimile: +33 (0)3 21 15 50 73 Contact Person: Fadwa Bahr, Quality and Regulatory Affairs Manager Date Prepared: March 9, 2021 ### Name of Device and Name/Address of Sponsor CLARIANCE, Idys® LLIF 3DTi ### Common or Usual Name Lumbar Intervertebral Body Fusion Device with Bone Graft ### Classification Name Class II, 21 CFR §888.3080 - Intervertebral body fusion device, OVD ### Predicate Devices Idys® ALIF ZP 3DTi, CLARIANCE SAS (K200920): primary predicate (screws, manufacturing process, cleaning, sterilization and packaging validation) Idys® ALIF System, CLARIANCE SAS (K172083): additional predicate (system, instruments mechanical performance) Idys® PLIF CLARIANCE SAS (K131178): additional predicate (mechanical performance) InFill® Interbody Fusion Devices, Pinnacle Spine Group, LLC (K152259) (cage size and lateral approach reference device) SIRION Lateral Lumbar Interbody Fusion System, Astura Medical, LLC (K192006) (cage size and lateral approach reference device) {4}------------------------------------------------ ### Intended Use / Indications for Use The Idys® LLIF 3DTi system is intended for use in patients with degenerative disc disease (DDD) at one (1) or two (2) contiguous level(s) of the lumbosacral spine (L2-S1). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. These DDD patients may also have up to Grade | Spondylolisthesis or retrolisthesis at the involved level(s). These patients should be skeletally mature and have had at least six (6) months of non-operative treatment. The Idys® LLIF 3DTi system is intended to be used with bone graft and/or allogeneic bone graft composed of cancellous and/or corticocancellous bone and with cleared supplemental fixation in addition to the integrated plate and screws. ## Technological Characteristics The Idys® LLIF 3DTi is designed for use as a lumbar intervertebral body fusion system. The device is manufactured from medical grade Titanium alloy using an additive manufacturing method and is to be used with bone graft and/or allogeneic bone graft composed of cancellous and/or corticocancellous bone. The cage has a shape which restores the intervertebral height and lordosis. The cage contains two (2) slots to receive the bone graft to promote the fusion process between the endplates. The Idys® LLIF 3DTi is a system intended to be used with a plate and two (2) bone screws, bone graft and supplemental fixation that has been authorized for surgical use in the lumbar spine. The Idys® LLF 3DTi components are made of compliant ASTM F136 Titanium alloy. ## Performance Data ### Biocompatibility As there have been no changes to the manufacturing methods or patient contacting materials as compared to the primary predicate, no new biocompatibility testing was required to establish equivalence. Confirmatory testing per ISO 10993-5 and -11 had been performed. ### Sterility and Cleaning Sterilization validation per ISO 11737 and ISO 11137 has been successfully completed. Cleaning validation has shown acceptable limits of residues. ## Mechanical Testing Mechanical testing according to ASTM F2077 and ASTM F2267 were used to support substantial equivalence with Idys® ALIF System and Idys® PLIF, (cleared respectively in K172083 and K131178). Specifically, CLARIANCE performed static and dynamic axial compression testing, static and dynamic compression shear testing, expulsion testing, static torsion testing, and particle characterization, all of which demonstrated the substantial equivalence of the system to legally marketed devices. {5}------------------------------------------------ ### Substantial Equivalence The Idys® LLIF 3DTi system and its predicates are designed for use as lumbar intervertebral body fusion devices. All devices are composed of cages or "interbody spacers" available with various configurations to accommodate patient's anatomy and are to be used with the provided plates and screws and supplemental fixation. The Idys® LLIF 3DTi and Idys® ALIF ZP 3DTi (K200920) cages are made using the same additive manufacturing method using titanium alloy per ASTM F3001 and results in the same. porous structure. In contrast, the Idys® ALIF System (K172083), Idys® PLIF (K131178), InFill® Interbody Fusion Devices (K152259) and SIRION Lateral Lumbar Interbody Fusion cages are made of PEEK OPTIMA LT1® per ASTM 2026 (while the SIRON can also contain HA). Differences in cage material do not raise difference questions, as both devices raise the same questions regarding biocompatibility and mechanical performance. Both Titanium Alloy Ti6AI4V ELI and PEEK are well-known materials that have been used for many years, and which are standardized by ISO/ASTM as implantable grade of materials. Mechanical testing has shown that this structure does not have an adverse impact on the mechanical performance of the Idys® LLIF 3DTi system. The use of porous lattice allows the 3DTi cages to have similar stiffness than cages made of PEEK, avoiding stress-shielding and providing a scaffold for bone fusion. The Idys® LLIF 3DTi cages, the SIRION LLIF System Devices (K192006) and the InFill® Interbody Fusion Devices (K152259) cages are inserted using a lateral approach and. accordingly, feature a similar outer shape and design. All three devices are long cages with a bulleted nose and contain slots to allow the incorporation of bone graft which is essential to promoting the fusion process. The difference in the number of slots for bone graft between the ldys® LLIF 3DTi, InFill® V2 Lateral Interbody Fusion (K152259) and SIRION Lateral Lumbar Interbody Fusion System (K192006) predicates do not raise new or different issues of safety and effectiveness since the volume available for bone graft is equivalent. Unlike the InFil® V2 Lateral Interbody Fusion (K152259) and SIRION Lateral Lumbar Interbody Fusion System (K192006) predicates, each of the superior and inferior surfaces of the Idys® LLIF 3DTi cages do not have teeth since the roughness of the porous structure is sufficient to grip the surface of the vertebral endplates and help resist expulsion. Although there are no teeth on the superior and inferior surfaces, the expulsion testing has demonstrated adequate resistance to expulsion. In terms of configurations, the Idys® LLIF 3DTi system are similar to those of the cleared InFill® V2 Lateral Interbody Fusion predicate (K152259). Additionally, all Idys® LLIF 3DTi cage heights are within SIRION (K192006) range. The Idys® LLIF 3DTi cages are available with various footprints with different heights ranges and lordotic angles. ## Conclusions The Idys® LLIF 3DTi is substantially equivalent to Idys® ALIF ZP 3DTi (K200920). The Idys® LLIF 3DTi has the same intended uses and similar indications, technological characteristics, and principles of operation as its predicate device. The minor technological differences between the Idys® LLIF 3DTi and its predicate device do not raise any new issues of safety or effectiveness. Performance data demonstrate that the Idys® LLIF 3DTi is as safe and effective {6}------------------------------------------------ as its predicate. Thus, the Idys® LLIF 3DTi is substantially equivalent.
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%